antiviral and associated therapy - versus antiviral and associated therapy - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.12 [0.02, 0.62]< 10%1 study (1/-)99.4 %NAnot evaluable crucial-
deaths 0.94 [0.51, 1.73]< 10%1 study (1/-)57.9 %NAnot evaluable crucial-
deaths (time to event analysis only) 0.94 [0.51, 1.73]< 10%1 study (1/-)57.9 %NAnot evaluable crucial-
hospital discharge 0.62 [0.28, 1.37]> 10%1 study (-/1)11.9 %NAnot evaluable important-
mechanical ventilation 0.14 [0.03, 0.71]< 10%1 study (1/-)99.1 %NAnot evaluable important-
ICU admission 1.42 [0.68, 2.99]< 10%1 study (1/-)17.7 %NAnot evaluable non important-
recovery 8.25 [1.61, 42.37]> 10%1 study (1/-)99.4 %NAnot evaluable non important-

safety endpoints 00

adverse events 0.11 [0.01, 2.17]< 10%1 study (1/-)92.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.